心臟即时检测设备市场按产品类型、最终用户、技术、样品类型和应用划分－2025-2032年全球预测

预计到 2032 年，心臟即时检测设备市场规模将成长 40 亿美元，复合年增长率为 12.85%。

关键市场统计数据
基准年2024年	15.2亿美元
预计年份：2025年	16.9亿美元
预测年份 2032	40亿美元
复合年增长率 (%)	12.85%

一份简洁而照护现场心臟诊断指南，为临床需求、业务重点和策略应用驱动因素提供了框架。

床边心臟诊断设备已成为现代心血管护理的关键工具，重塑了临床医生检测和应对急性心臟事件的方式。这些平台可在患者床边或床边提供生物标记资讯，缩短诊断时间，并支援快速制定治疗决策。对于许多医疗机构而言，缩短急性冠状动脉症候群和心臟衰竭加重等疾病的诊断时间是临床工作的重中之重，而床边诊断解决方案透过提供快速、可操作的检测结果，并将其整合到急诊和住院工作流程中，直接助力实现这一目标。

从营运角度来看，医院和诊所重视那些兼具分析性能、易用性、低维护成本以及与电子健康记录无缝整合等优势的仪器。检测化学和讯号检测技术的进步提高了灵敏度和特异性，增强了临床医生对即时检测结果的信心。因此，临床效用、工作流程相容性和整体拥有成本 (TCO) 等因素越来越成为推动仪器应用的重要因素。相关人员在评估对心臟即时检测技术的策略性投资时，不仅会考虑诊断准确性，还会考虑设备体积、耗材物流、员工培训需求以及影响长期营运可行性的监管路径。

综上所述，这些因素意味着即时检验（POC）设备是加速临床诊疗和提高系统效率的工具。哪些平台最终能成为急诊和门诊的标准设备，将取决于製造商和医疗系统能否使产品设计与临床需求和报销实际情况相符。

技术进步、临床工作流程重新设计以及不断变化的报销预期如何改变心臟照护现场诊断的采用和效用

由于技术创新、医疗模式的转变以及人们对快速诊断准确性的日益增长的期望，心臟就地检验领域正经历着显着的变化。在技​​术方面，检测组件的小型化、电化学和光学检测系统的整合以及免疫测量方法的改进，在提高分析性能的同时，也缩短了获得结果的时间。这些进展拓展了即时侦测的可靠应用场景，使其涵盖了院前急救和资源有限的诊所环境。

同时，医疗服务模式也在不断演变。急诊和心臟监护病房越来越依赖更快速的诊断资讯来优先处理患者并管理床位流动。这些临床压力，加上更广泛的去中心化医疗模式，推动了对功​​能强大的床边检测平台的需求，这些平台能够提供实验室级别的检测结果，而无需像中心实验室那样耗时。同时，支付方和医疗系统也仔细检视医疗服务的价值，倾向于那些能够透过早期疗育和减少住院次数来显着降低后续成本的解决方案。最终，这些因素累积促成了医疗服务从早期试验阶段转向主流临床整合的转变。

监管和报销框架也在不断调整，医疗机构正在明确床边检测设备的性能预期，而支付方也在完善医疗保险政策以反映临床证据。因此，能够证明其产品具有持续的分析有效性、营运韧性和可衡量的临床影响的製造商，更有可能获得更高的市场认可。摘要，技术进步、临床工作流程的重新设计和经济课责正在共同推动心臟床边检测技术在促进更快、更有效率的医疗保健方面发挥变革性作用。

评估2025年关税主导的供应链压力和策略采购应对措施对设备可用性、采购经济性和业务连续性的影响

贸易政策的发展，包括计划于2025年在美国实施的关税调整，为心臟即时检测生态系统中的製造商、经销商和医疗保健采购商带来了新的考量。这些关税将影响零件采购、定价策略和供应链韧性，促使製造商重新评估其采购布局，并探索其他製造地和供应商合作关係。为此，许多公司已开始实现供应链多元化，以降低对单一国家的风险敞口，并在不影响临床性能的前提下维持利润率。

这些关税主导的压力也影响分销经济。经销商和医院采购团队正在调整合约条款和库存策略，以应对潜在的成本波动。关税的影响促使一些供应商加快组装本地化组装，并签订长期零件合同，以稳定单价并缩短补货週期。此外，关税的影响也促使人们更加关注投入成本的细分，提高了供应商和客户之间的透明度，使他们能够预测成本调整，而不是被动应对。

从临床营运角度来看，不断上升的成本压力促使医疗系统优先选择能够显着提高工作流程效率并减少后续资源消耗的设备，例如缩短急诊停留时间和减少不必要的住院。最终，这迫使相关人员考虑如何在应对经济变化的同时维持临床服务能力，在控製成本和持续获得高品质诊断之间取得平衡，并推动策略性供应链规划。

全面的細項分析，重点在于生物标记选择、终端使用者工作流程需求、检测技术、样本偏好和关键心臟应用。

对心臟就地检验市场进行细緻的细分，揭示了产品、终端用户、技术、样本类型和应用等方面的动态变化，这些因素共同塑造了市场需求和发展重点。产品差异化主要围绕在生物标记展开，例如脑钠肽（BNP）、肌酸激酶同工酶（CK-MB）、肌红蛋白和肌钙蛋白，其中肌钙蛋白检测可进一步细分为肌钙蛋白I和肌钙蛋白T。在某些临床情况下，CK-MB和肌红蛋白仍然具有效用，因为补充资讯和历史数据对比在这些情况下具有临床意义。

终端使用者细分涵盖诊所、诊断实验室和医院，其中医院包括心臟监护病房和急诊。急诊室优先考虑速度和高效的工作流程，而心臟监护病房则重视连续测量功能以及与连续监测系统的整合。诊所和门诊中心重视紧凑、低维护的设备，这些设备有助于分诊和随访，且不会增加实验室营运成本。采用即时侦测平台的诊断实验室通常是为了在尖峰时段分流高通量分析仪，或将服务扩展到卫星站点。

技术差异包括比色法、电化学法和免疫检测法，其中免疫免疫检测可细分为萤光和侧向流动法。比色法在检测某些分析物时具有简单性和成本优势；电化学平台具有小型化和低功耗的优势；而免疫检测能提供检测低丰度心臟生物标记所需的灵敏度。在样本类型方面，主要考虑血浆、血清和全血。全血样本无需离心步骤，提高了床边应用的便利性；而当需要实验室整合和标准化处理时，血浆和血清样本则更为理想。按应用领域划分，这些设备主要针对急性冠状动脉症候群和心臟衰竭等应用场景而开发，每个场景对灵敏度、週转时间和长期监测的要求各不相同。了解这些细分领域有助于相关人员将产品设计、临床检验和商业化策略与最终用户的实际营运需求相匹配。

在全球范围内，区域需求和医疗保健系统结构的差异将决定照护现场设备的功能优先顺序、部署策略和普及路径。

区域需求驱动因素和医疗保健系统结构导致全球即时心臟诊断设备（POC）的评估和采用路径有显着差异。在美洲，急诊通讯协定和广泛的门诊病人网路推动了对可在医院和门诊诊所部署的快速、整合式即时诊断解决方案的需求。该地区的医疗系统通常优先考虑与电子健康记录的互通性和简化的计费流程，从而影响产品功能需求和整合服务。

欧洲、中东和非洲不同的法规环境和实验室基础设施水准导致了不同的应用路径。欧洲主要医疗中心的高级急诊医院优先考虑分析的严谨性和合规性，而中东和非洲部分地区资源有限、缺乏集中式实验室的机构则正在采用即时检测平台来扩大诊断能力。在这些地区，稳定性强、维护成本低、训练资料清晰的设备将得到更广泛的应用。

亚太地区正经历着快速普及，这主要得益于急诊设施的扩张、分散式医疗模式投资的增加以及对本地化生产和分销的强烈需求。从大都会圈三级医院到分散式社区诊所，各种临床环境都对高通量和便携式即时检测（POC​​）解决方案产生了需求。根据不同地区，买家会寻求检验的临床性能、可靠的供应链以及对改善患者就诊流程和临床决策的显着贡献，但这些标准的相对权重会因各地区医疗体系的优先事项和报销框架而异。

竞争格局由现有企业、敏捷的创新者、策略伙伴关係以及不断演进的服务模式所驱动，这些模式使产品性能与临床结果保持一致。

心臟就地检验领域的竞争格局由传统诊断设备製造商、照护现场专业公司和新兴技术参与企业共同构成。市场现有企业利用与医院和诊所建立的稳固关係，提供广泛的服务网络和丰富的监管经验，从而促进医院层面的采购和长期服务协议。这些公司通常透过投资平台互通性和扩展检测专案功能来增强客户维繫，从而支援在单一装置中实现多种检测策略。

即时检测（POC​​）专家正积极寻求在急诊医学、农村医疗和院前救护急救等领域的细分市场应用机会，重点关注快速出结果和紧凑的仪器设计。产品开发的灵活性使得检测方法和使用者介面能够快速迭代，但拓展销售和服务网路仍然是物流的重点。利用新型检测化学技术和数位分析的参与企业带来了竞争压力，他们承诺提供更佳的分析效果和更好的使用者体验，从而减轻培训负担并减少操作人员的差异。

随着大型企业透过引入即时检测（POC​​）能力来丰富其产品组合，以及创新者积极寻求通路准入和监管环境，策略伙伴关係和收购活动持续重塑着竞争格局。同时，试剂租赁、订阅定价和基于结果的合约等服务模式也正在被探索，以使供应商的激励机制与临床影响保持一致。这些竞争措施将共同推动仪器性能、使用者奖励和商业性灵活性的持续提升，从而惠及那些既需要可靠性又需要适应性的医疗保健系统。

医疗设备製造商和医疗系统可采取的切实可行的策略重点，以推动产品应用、降低供应风险并展现可衡量的临床和营运价值。

产业领导者若想巩固其在心臟即时检测（POC​​）市场的地位，应优先考虑临床证据的累积、模组化产品设计以及稳健的供应链策略。尤其引人注目的是，能够将检测与缩短住院时间、加快治疗决策速度以及提高分诊准确性联繫起来的证据。同时，允许添加检测项目和软体升级的模组化平台，既有助于保护客户的投资，又能帮助供应商有效率地扩展产品系列。

从营运角度来看，零件供应多元化和探索本地组装方案可以降低关税和物流方面的风险。与医疗系统采购团队建立透明的关係，考虑整体拥有成本，并提供灵活的商业模式（例如分包和绩效合约），可以降低采用门槛。从使用者体验角度来看，简化介面、减少维护需求并提供全面的训练资源可以减少操作摩擦，并提高照护现场的资料品质。

最后，推行互通性标准并与电子健康记录提供者合作，将有助于临床工作流程的整合，并支持更广泛的机构采用。透过结合临床检验、灵活的商业化、弹性采购以及对以使用者为中心的设计的不懈关注，领导者可以最大限度地提高采用的可能性，并为医护团队和患者带来可衡量的价值。

采用严谨的混合方法研究途径，结合临床医师访谈、采购洞察、监管整合和多源三角验证，以获得可靠的策略资讯。

本分析所依据的研究采用了混合方法，以确保研究的深度、多方验证和实用性。主要研究包括对急诊和心臟监护室的临床医生、医院和诊所的采购负责人以及医疗器材製造商的产品经理进行结构化访谈。这些访谈揭示了实际工作流程需求、采购标准和器械功能优先级，提供了仅凭定量资料集无法捕捉到的细緻观点。

二级研究整合了监管指南、临床实践指南和同行评审文献，以确定生物标记的效用、预期设备性能以及诊疗路径整合的现状。技术趋势和供应链发展方面的资讯来自行业简报和公开的监管文件。在条件允许的情况下，我们透过比较一级和二级来源，识别一致的主题，并标记出存在分歧之处以便进行更深入的调查，从而对调查方法进行了交叉检验。

透过系统性的资料清理、质性访谈的主题编码以及对研究结果的结构化综合，确保了分析的严谨性，从而得出可操作的见解。品管步骤包括对解释性结论的同行评审以及对技术声明的专家验证。最终形成了一份多方面的检验，旨在支持临床、商业和营运领域的策略决策，其透明的方法论有助于结果的可重复性，并在需要更详细资讯时进行有针对性的后续跟进。

整合临床、技术和营运方面的必要因素，将决定哪些照护现场心臟技术能够实现持续的临床整合并产生影响。

总之，在技术进步、临床对快速决策的需求以及不断变化的采购重点的推动下，照护现场心臟诊断设备将在急诊和分散式医疗模式中发挥日益重要的作用。最具影响力的设备将是那些兼具实验室级性能、操作简便性、强大的互通性和供应链韧性的设备。从製造商和经销商到医院领导和临床医生，价值链上的所有利益相关人员必须在证据生成、用户体验和商业性安排方面达成一致，才能充分发挥床边心臟生物标记检测的潜力。

随着临床环境持续将速度、准确性和成本效益置于优先地位，能够实际改善患者就诊流程和临床疗效的能力很可能推动其更广泛应用。同时，地缘政治和政策发展将引发供应链的考量，企业必须透过多元化采购和在地化能力积极应对。展望未来，先进的检测化学技术、智慧型装置平台和以结果为导向的商业模式的融合，将定义心臟即时检测（POC​​）下一阶段的成长和整合。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• 手持式即时检测分析仪上灵敏的心臟生物标记检测方法的快速发展，提高了心肌梗塞的早期检出率。
• 在可携式心臟即时检测设备中采用人工智慧驱动的心电图判读模组，以实现高效的远端分诊
• 开发心臟衰竭和心肌梗塞综合筛检的肌钙蛋白和利钠肽综合检测平台
• 扩展智慧型手机整合式心臟即时检测系统，以实现即时数据共用和远端医疗连接。
• 实现用于心臟照护现场的微流体实验室晶片平台，该平台具有超低样本量和快速週转的特点
• 加快对CLIA豁免的高灵敏度肌钙蛋白检测的监管，将推动其在门诊和急诊环境中的更广泛应用。
• 心臟即时检测设备製造商与远端医疗提供者之间的策略合作，能够提升分散式急性心臟照护的效率。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 心臟即时检测设备市场（依产品类型划分）

• BNP
• CK-MB
• 肌红蛋白
• 肌钙蛋白
  • 肌钙蛋白 I
  • 肌钙蛋白T

第九章：依最终使用者分類的心臟即时检测设备市场

• 诊所
• 诊断实验室
• 医院
  • 心臟监护病房
  • 急诊部

第十章：依技术分類的心臟即时检测设备市场

• 比色分析
• 电化学
• 免疫检测
  • 萤光
  • 侧向流

第十一章：以样本类型分類的心臟即时检测设备市场

• 电浆
• 血清
• 全血

第十二章：心臟即时检测设备市场（依应用领域划分）

• 急性冠状动脉症候群
• 心臟衰竭

第十三章：心臟即时侦测设备市场（依地区划分）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十四章：心臟即时检测设备市场（依组别划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十五章：各国心臟即时检测设备市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • F. Hoffmann-La Roche Ltd
  • Abbott Laboratories
  • Siemens Healthineers AG
  • Danaher Corporation
  • Becton Dickinson and Company
  • bioMerieux SA
  • Quidel Corporation
  • Nova Biomedical, Inc.
  • Trinity Biotech plc
  • Chembio Diagnostics Systems, Inc.

The Cardiac POC Testing Devices Market is projected to grow by USD 4.00 billion at a CAGR of 12.85% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 1.52 billion
Estimated Year [2025]	USD 1.69 billion
Forecast Year [2032]	USD 4.00 billion
CAGR (%)	12.85%

A concise yet compelling orientation to point-of-care cardiac diagnostics that frames clinical imperatives, operational priorities, and strategic adoption drivers

Point-of-care cardiac diagnostic devices have emerged as pivotal tools in modern cardiovascular care pathways, reshaping how clinicians detect and respond to acute cardiac events. These platforms deliver biomarker insights at or near the patient bedside, shortening diagnostic timelines and empowering quicker therapeutic decisions. The clinical priority for many providers is to reduce time-to-diagnosis for conditions such as acute coronary syndromes and heart failure exacerbations, and point-of-care solutions contribute directly to that objective by providing rapid, actionable results that integrate into emergency and inpatient workflows.

Operationally, hospitals and clinics value devices that balance analytical performance with ease of use, minimal maintenance, and seamless integration into electronic health records. Advances in assay chemistry and signal detection have improved sensitivity and specificity, which in turn increases clinician confidence in point-of-care results. As a result, adoption is increasingly driven by a combination of clinical utility, workflow compatibility, and total cost of ownership considerations. When stakeholders evaluate strategic investments in cardiac point-of-care technologies, they weigh not only diagnostic accuracy but also device footprint, consumable logistics, staff training requirements, and regulatory pathways that affect long-term operational viability.

Taken together, these factors frame the business case for point-of-care cardiac devices: they are instruments of clinical acceleration and systems efficiency. Moving forward, the ability of manufacturers and health systems to align product design with clinical requirements and reimbursement realities will determine which platforms become standard fixtures in acute care and ambulatory settings.

How technological advances, clinical workflow redesign, and evolving reimbursement expectations are jointly transforming adoption and utility of cardiac point-of-care diagnostics

The landscape of cardiac point-of-care testing is undergoing transformative shifts driven by technological innovation, changing care models, and heightened expectations for rapid diagnostic precision. On the technology front, miniaturization of assay components, integration of electrochemical and optical detection systems, and refinement of immunoassay formats have collectively improved analytical performance while reducing time-to-result. These developments expand the clinical contexts where point-of-care testing can be reliably deployed, including pre-hospital triage and resource-constrained clinic environments.

Concurrently, care delivery paradigms are evolving; emergency departments and cardiac care units increasingly rely on faster diagnostic information to prioritize patients and manage bed flow. This clinical pressure, coupled with a broader move toward decentralized care, elevates demand for robust point-of-care platforms that deliver laboratory-grade results without the delays associated with central labs. Meanwhile, payers and health systems are scrutinizing value, favoring solutions that demonstrably reduce downstream costs through earlier intervention and reduced admissions. The cumulative effect is a shift from early adopter experimentation to mainstream clinical integration.

Regulatory and reimbursement frameworks are also adapting, with agencies clarifying performance expectations for near-patient devices and payers refining coverage policies that reflect clinical evidence. As a result, manufacturers that can demonstrate consistent analytical validity, operational resilience, and measurable clinical impact will secure stronger uptake. In summary, technological advancement, clinical workflow redesign, and economic accountability are converging to transform how cardiac point-of-care diagnostics contribute to faster, more effective care.

Assessment of 2025 tariff-driven supply-chain pressures and strategic sourcing responses shaping device availability, procurement economics, and operational continuity

Trade policy developments, including tariff adjustments introduced in the United States in 2025, have created a new set of considerations for manufacturers, distributors, and healthcare purchasers in the cardiac point-of-care ecosystem. Tariffs influence component sourcing, pricing strategies, and supply-chain resilience, prompting manufacturers to reassess procurement footprints and to explore alternative manufacturing locations or supplier partnerships. In response, many firms have initiated supply-chain diversification efforts to mitigate single-country exposure and to preserve margin structures without compromising clinical performance.

These tariff-driven pressures also affect distribution economics. Distributors and hospital procurement teams are recalibrating contract terms and inventory strategies to accommodate potential cost variability. For some vendors, the tariff environment accelerated plans to localize assembly or to secure long-term component agreements, which helps stabilize unit costs and shortens replenishment cycles. Additionally, tariff impacts have prompted closer scrutiny of input cost breakdowns and encouraged transparency between suppliers and customers so that adjustments can be anticipated rather than reacted to.

From a clinical operations perspective, the specter of elevated costs has encouraged health systems to prioritize devices that offer clear workflow efficiencies and that reduce downstream resource utilization, such as shorter emergency department stays or fewer unnecessary admissions. Ultimately, tariffs serve as a catalyst for strategic supply-chain planning, compelling stakeholders to balance cost containment with uninterrupted access to high-quality diagnostics and to consider operational levers that sustain clinical capacity while absorbing economic shifts.

A comprehensive segmentation analysis highlighting biomarker selection, end-user workflow demands, detection technologies, sample preferences, and primary cardiac applications

A nuanced segmentation of the cardiac point-of-care testing market reveals distinct product, end-user, technological, sample-type, and application dynamics that collectively shape demand and development priorities. Product differentiation centers on biomarkers such as BNP, CK-MB, Myoglobin, and the troponins, with troponin assays further divided into Troponin I and Troponin T. Troponin-based testing remains central to acute chest pain pathways given its diagnostic specificity for myocardial injury, while BNP assays are prioritized in heart failure assessment scenarios. CK-MB and myoglobin retain utility in certain contexts where complementary information or historical comparison is clinically useful.

End-user segmentation spans clinics, diagnostic laboratories, and hospitals, the latter encompassing both cardiac care units and emergency departments. Emergency settings prioritize speed and ruggedized workflows, whereas cardiac care units emphasize serial measurement capabilities and integration with continuous monitoring systems. Clinics and outpatient centers value compact, low-maintenance devices that facilitate triage and follow-up without heavy laboratory overhead. Diagnostic laboratories that adopt point-of-care platforms often do so to offload high-throughput analyzers during peak demand or to extend services to satellite sites.

Technological differentiation includes colorimetric, electrochemical, and immunoassay approaches, with immunoassays further divided into fluorescence-based and lateral flow formats. Colorimetric methods offer simplicity and cost advantages for certain analytes, electrochemical platforms excel in miniaturized, low-power architectures, and immunoassays deliver the sensitivity required for low-abundance cardiac biomarkers. Sample-type considerations cover plasma, serum, and whole blood; whole blood compatibility increases usability at the bedside by eliminating centrifugation steps, while plasma and serum samples are preferred when laboratory integration and standardized processing are required. Application-wise, devices are developed primarily for acute coronary syndrome and heart failure use cases, each imposing different sensitivity, turnaround time, and longitudinal monitoring requirements. Understanding these segmentation layers allows stakeholders to align product design, clinical validation, and commercialization strategies with the operational realities of intended end users.

Regional demand and health-system architecture differences that dictate point-of-care device feature priorities, deployment strategies, and adoption pathways across global territories

Regional demand drivers and health-system architectures create meaningful variation in how point-of-care cardiac diagnostics are evaluated and implemented across global geographies. In the Americas, emergency care protocols and extensive outpatient networks drive demand for rapid, integrated point-of-care solutions that can be deployed across hospitals and ambulatory clinics. Health systems in this region often emphasize interoperability with electronic health records and streamlined billing practices, which shapes product feature requirements and integration services.

In Europe, Middle East & Africa, heterogeneous regulatory environments and varying levels of laboratory infrastructure produce a diverse set of adoption pathways. High-acuity hospitals in major European centers prioritize analytical rigor and regulatory compliance, whereas resource-limited settings in parts of the Middle East and Africa adopt point-of-care platforms to extend diagnostic capacity where centralized laboratories are scarce. In these contexts, devices that combine robustness, minimal maintenance, and clear training materials achieve broader traction.

The Asia-Pacific region demonstrates rapid uptake driven by expanding acute care facilities, growing investment in decentralized care models, and strong interest in localization of manufacturing and distribution. Diverse clinical settings-from metropolitan tertiary hospitals to decentralized community clinics-create demand for both high-throughput and handheld point-of-care solutions. Across regions, purchasers look for validated clinical performance, reliable supply chains, and demonstrable contributions to improved patient flow and clinical decision-making, but the relative weighting of these criteria varies based on local health-system priorities and reimbursement frameworks.

Competitive landscape dynamics driven by incumbents, agile innovators, strategic partnerships, and evolving service models that align product performance with clinical outcomes

Competitive dynamics in the cardiac point-of-care testing sector are shaped by a mix of legacy diagnostic manufacturers, specialized point-of-care firms, and emerging technology entrants. Market incumbents leverage established relationships with hospitals and clinics, providing broad service networks and deep regulatory experience that facilitate hospital-level procurement and long-term service agreements. These organizations often invest in platform interoperability and extended menu capabilities to reinforce customer retention and to support multi-assay strategies within a single device footprint.

Specialized point-of-care firms focus on speed-to-result and compact device design, pursuing niche adoption opportunities in emergency medicine, rural healthcare, and pre-hospital care. Their agility in product development enables rapid iteration on assay formats and user interfaces, although scaling distribution and service networks remains a logistical focus. New entrants leveraging novel detection chemistries or digital analytics introduce competitive pressure by promising either analytical improvements or enhanced user experiences that reduce training burdens and operator variability.

Strategic partnerships and acquisition activity continue to shape the competitive landscape as larger firms supplement portfolios with point-of-care capabilities and as innovators seek channel access and regulatory expertise. In parallel, service models such as reagent leasing, subscription pricing, or outcome-based contracts are being explored to align vendor incentives with clinical impact. Collectively, these competitive behaviors drive continuous improvement in device performance, user experience, and commercial flexibility, benefitting health systems that require both reliability and adaptability.

Actionable strategic priorities for device makers and health systems to enhance adoption, mitigate supply risks, and demonstrate measurable clinical and operational value

Industry leaders seeking to strengthen their position in the cardiac point-of-care market should prioritize a combination of clinical evidence generation, modular product design, and resilient supply-chain strategies. Investing in robust clinical validation studies that demonstrate real-world impact on patient pathways will accelerate adoption by hospitals and payers; evidence that links testing to reduced length of stay, faster therapeutic decisions, or improved triage accuracy is particularly persuasive. Concurrently, modular platforms that allow incremental assay additions and software upgrades help customers protect their investment while enabling vendors to scale product portfolios efficiently.

On the operational side, diversifying component supply and considering regional assembly options will mitigate tariff and logistics-related vulnerabilities. Transparent engagement with health-system procurement teams to align total cost of ownership considerations and to offer flexible commercial models-such as reagent-as-a-service or outcome-linked contracts-can lower adoption barriers. From a user experience perspective, simplifying interfaces, minimizing maintenance needs, and providing comprehensive training resources will reduce operational friction and improve data quality at the point of care.

Finally, pursuing interoperability standards and partnering with electronic health record providers enhances clinical workflow integration and supports broader institutional adoption. By combining clinical validation, flexible commercialization, resilient sourcing, and a relentless focus on user-centered design, leaders can maximize adoption potential and deliver measurable value to care teams and patients alike.

A rigorous mixed-methods research approach combining clinician interviews, procurement insights, regulatory synthesis, and multi-source triangulation for reliable strategic intelligence

The research underpinning this analysis employed a mixed-methods approach to ensure depth, triangulation, and practical relevance. Primary research included structured interviews with clinicians from emergency departments and cardiac care units, procurement leaders from hospitals and clinics, and product managers across device manufacturers. These conversations illuminated real-world workflow needs, procurement criteria, and device feature priorities, offering nuanced perspectives that quantitative datasets alone cannot capture.

Secondary research synthesized regulatory guidance, clinical practice guidelines, and peer-reviewed literature to contextualize biomarker utility, device performance expectations, and care-pathway integration. Information on technology trends and supply-chain developments was corroborated through industry briefings and publicly available regulatory filings. Where possible, methodology cross-validation was achieved by comparing primary insights with secondary sources to identify consistent themes and to flag divergent viewpoints for deeper inquiry.

Analytical rigor was maintained through systematic data cleaning, thematic coding of qualitative interviews, and structured synthesis of findings to produce actionable insights. Quality control steps included peer review of interpretive conclusions and verification of technical claims with subject-matter experts. The result is a multi-perspective assessment designed to support strategic decisions across clinical, commercial, and operational domains, with transparent methods that facilitate reproducibility and targeted follow-up research when deeper granularity is required.

Synthesis of clinical, technological, and operational imperatives that will determine which point-of-care cardiac technologies achieve sustained clinical integration and impact

In conclusion, point-of-care cardiac diagnostics are positioned to play an increasingly central role in acute care and decentralized care models, driven by technological progress, clinical need for rapid decision-making, and evolving procurement priorities. The most impactful devices will be those that pair laboratory-quality performance with operational simplicity, robust interoperability, and supply-chain resilience. Stakeholders across the value chain-from manufacturers and distributors to hospital leaders and clinicians-must align on evidence generation, user experience, and commercial arrangements to realize the full potential of bedside cardiac biomarker testing.

As clinical environments continue to prioritize speed, accuracy, and cost-effectiveness, the ability to demonstrate tangible improvements in patient flow and clinical outcomes will be a decisive factor in broader adoption. Simultaneously, geopolitical and policy developments introduce supply-chain considerations that organizations must proactively address through diversified sourcing and localized capabilities. Looking ahead, the intersection of refined assay chemistries, intelligent device platforms, and outcome-oriented commercial models will define the next phase of growth and integration for cardiac point-of-care testing.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Rapid evolution of high-sensitivity cardiac biomarker assays in handheld POC analyzers to improve early MI detection
• 5.2. Adoption of AI-driven ECG interpretation modules in portable cardiac POC devices for efficient remote triage
• 5.3. Development of integrated troponin and natriuretic peptide detection platforms for comprehensive heart failure and myocardial infarction screening
• 5.4. Expansion of smartphone-integrated cardiac POC testing systems enabling real-time data sharing and telemedicine connectivity
• 5.5. Implementation of microfluidic lab-on-a-chip platforms in cardiac point-of-care assays for ultra-low sample volumes and accelerated turnaround
• 5.6. Regulatory acceleration of CLIA-waived high-sensitivity troponin tests facilitating wider adoption in outpatient and emergency settings
• 5.7. Strategic collaborations between cardiac POC device manufacturers and telehealth providers to enhance decentralized acute cardiac care delivery

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cardiac POC Testing Devices Market, by Product Type

• 8.1. BNP
• 8.2. CK-MB
• 8.3. Myoglobin
• 8.4. Troponin
  • 8.4.1. Troponin I
  • 8.4.2. Troponin T

9. Cardiac POC Testing Devices Market, by End User

• 9.1. Clinics
• 9.2. Diagnostic Laboratories
• 9.3. Hospital
  • 9.3.1. Cardiac Care Unit
  • 9.3.2. Emergency Department

10. Cardiac POC Testing Devices Market, by Technology

• 10.1. Colorimetric
• 10.2. Electrochemical
• 10.3. Immunoassay
  • 10.3.1. Fluorescence
  • 10.3.2. Lateral Flow

11. Cardiac POC Testing Devices Market, by Sample Type

• 11.1. Plasma
• 11.2. Serum
• 11.3. Whole Blood

12. Cardiac POC Testing Devices Market, by Application

• 12.1. Acute Coronary Syndrome
• 12.2. Heart Failure

13. Cardiac POC Testing Devices Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Cardiac POC Testing Devices Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Cardiac POC Testing Devices Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. F. Hoffmann-La Roche Ltd
  • 16.3.2. Abbott Laboratories
  • 16.3.3. Siemens Healthineers AG
  • 16.3.4. Danaher Corporation
  • 16.3.5. Becton Dickinson and Company
  • 16.3.6. bioMerieux SA
  • 16.3.7. Quidel Corporation
  • 16.3.8. Nova Biomedical, Inc.
  • 16.3.9. Trinity Biotech plc
  • 16.3.10. Chembio Diagnostics Systems, Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GCC CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. EUROPEAN UNION CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. BRICS CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. G7 CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NATO CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. CARDIAC POC TESTING DEVICES MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 30. CARDIAC POC TESTING DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. CARDIAC POC TESTING DEVICES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY BNP, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY BNP, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY BNP, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY BNP, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY BNP, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY BNP, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CK-MB, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CK-MB, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CK-MB, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CK-MB, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CK-MB, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CK-MB, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY MYOGLOBIN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY MYOGLOBIN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY MYOGLOBIN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY MYOGLOBIN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY MYOGLOBIN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY MYOGLOBIN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN I, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN I, BY REGION, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN I, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN I, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN I, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN I, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN T, BY REGION, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN T, BY REGION, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN T, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN T, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN T, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN T, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CARDIAC CARE UNIT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CARDIAC CARE UNIT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CARDIAC CARE UNIT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CARDIAC CARE UNIT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CARDIAC CARE UNIT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CARDIAC CARE UNIT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY EMERGENCY DEPARTMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY EMERGENCY DEPARTMENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY EMERGENCY DEPARTMENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY EMERGENCY DEPARTMENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY EMERGENCY DEPARTMENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY EMERGENCY DEPARTMENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY COLORIMETRIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY COLORIMETRIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY COLORIMETRIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY COLORIMETRIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY COLORIMETRIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY COLORIMETRIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY ELECTROCHEMICAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY ELECTROCHEMICAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY ELECTROCHEMICAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY ELECTROCHEMICAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY ELECTROCHEMICAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY ELECTROCHEMICAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY FLUORESCENCE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY FLUORESCENCE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY FLUORESCENCE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY FLUORESCENCE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY FLUORESCENCE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY FLUORESCENCE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY LATERAL FLOW, BY REGION, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY LATERAL FLOW, BY REGION, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY LATERAL FLOW, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY LATERAL FLOW, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY LATERAL FLOW, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY LATERAL FLOW, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY PLASMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY PLASMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY PLASMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY PLASMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY PLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY SERUM, BY REGION, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY SERUM, BY REGION, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY SERUM, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY SERUM, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY SERUM, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY REGION, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY REGION, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY HEART FAILURE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY HEART FAILURE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 149. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 150. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 151. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 152. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 153. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2018-2024 (USD MILLION)
• TABLE 154. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2025-2032 (USD MILLION)
• TABLE 155. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 156. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 157. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
• TABLE 158. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2025-2032 (USD MILLION)
• TABLE 159. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 160. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 161. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
• TABLE 162. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
• TABLE 163. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 164. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 165. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 166. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 167. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 168. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 169. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 170. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 171. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2018-2024 (USD MILLION)
• TABLE 172. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2025-2032 (USD MILLION)
• TABLE 173. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 174. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 175. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
• TABLE 176. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2025-2032 (USD MILLION)
• TABLE 177. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 178. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 179. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
• TABLE 180. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
• TABLE 181. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 182. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 183. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 184. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 185. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 186. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 187. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 188. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 189. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2018-2024 (USD MILLION)
• TABLE 190. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2025-2032 (USD MILLION)
• TABLE 191. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 192. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 193. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
• TABLE 194. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2025-2032 (USD MILLION)
• TABLE 195. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 196. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 197. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
• TABLE 198. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
• TABLE 199. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 200. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 201. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 202. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 204. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 205. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 206. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 207. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2018-2024 (USD MILLION)
• TABLE 208. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2025-2032 (USD MILLION)
• TABLE 209. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 210. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 211. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
• TABLE 212. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2025-2032 (USD MILLION)
• TABLE 213. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 214. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 215. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
• TABLE 216. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
• TABLE 217. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 218. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 219. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 220. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 221. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 222. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 223. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 224. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 225. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2018-2024 (USD MILLION)
• TABLE 226. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2025-2032 (USD MILLION)
• TABLE 227. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 228. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 229. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
• TABLE 230. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2025-2032 (USD MILLION)
• TABLE 231. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 232. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 233. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
• TABLE 234. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
• TABLE 235. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 236. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 237. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 238. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 239. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 240. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 241. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 242. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 243. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2018-2024 (USD MILLION)
• TABLE 244. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2025-2032 (USD MILLION)
• TABLE 245. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 246. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 247. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
• TABLE 248. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2025-2032 (USD MILLION)
• TABLE 249. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 250. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 251. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
• TABLE 252. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
• TABLE 253. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 254. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 255. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 256. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 257. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 258. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 259. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 260. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 261. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2018-2024 (USD MILLION)
• TABLE 262. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2025-2032 (USD MILLION)
• TABLE 263. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 264. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 265. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
• TABLE 266. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2025-2032 (USD MILLION)
• TABLE 267. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 268. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 269. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
• TABLE 270. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
• TABLE 271. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 272. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 273. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 274. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 275. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 276. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 277. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 278. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 279. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2018-2024 (USD MILLION)
• TABLE 280. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2025-2032 (USD MILLION)
• TABLE 281. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 282. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 283. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
• TABLE 284. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2025-2032 (USD MILLION)
• TABLE 285. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 286. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 287. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
• TABLE 288. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
• TABLE 289. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 290. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 291. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 292. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 293. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 294. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 295. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 296. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 297. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 298. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 299. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2018-2024 (USD MILLION)
• TABLE 300. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2025-2032 (USD MILLION)
• TABLE 301. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 302. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 303. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
• TABLE 304. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2025-2032 (USD MILLION)
• TABLE 305. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 306. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 307. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
• TABLE 308. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
• TABLE 309. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 310. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 311. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 312. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 313. GCC CARDIAC POC TESTING DEVICES MARKET